A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company’s therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Financial Summary
| Share Statistics | CSLLY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $58,334.9 | $286.3 | 94% |
|
| Shares Out (Mil) | 480.4 | 54.2 | 88% |
|
| Institutional Ownership | 49.9% | 92.8% | 27% |
|
| Float (Mil) | 478.5 | 39.7 | 85% |
|
| Beta | 0.09 | 0.94 | 8% |
|
| Avg Daily Volume (000s) | 113 | 534 | 36% |
|
| Price Change (52-week) |
(16.7%) | 58.7% | 31% |
|
| Growth | CSLLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.9% | 13.6% | 54% |
|
| Net Income (5yr) | (25.3%) | (10.1%) | 16% |
|
| EPS (5yr) | (24.8%) | 16.0% | 11 |
|
| Dividends (5yr) | 5.6% | 0.0% | 94% |
|
| Cash Flow (5yr) | (25.0%) | (15.6%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CSLLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15,797 | $37 | 89% |
|
| Net Income (TTM) (Mil) | ($2,579) | ($43) | 0% |
|
| EPS (TTM) | ($5.351) | ($1.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | $3,512 | ($31) | 92% |
|
| Net Cash Flow (TTM) (Mil) | ($644) | $2 | 5% |
|
| Long-Term Debt (Q1) (Mil) | $9,754 | $4 | 91% |
|
| Enterprise Value (Q1) (Mil) | $67,459 | $160 | 94% |
|
| Valuation | CSLLY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.77 | na |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CSLLY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 51.1% | 64.2% | 63% |
|
| Net Margin | (16.3%) | (75.9%) | 18% |
|
| ROA | (7.1%) | (47.3%) | 28% |
|
| ROE | (15.1%) | (55.0%) | 25% |
|
| Liabilities to Assets | 51.5% | 29.6% | 44% |
|
| F-Score | na | 2 | na |
|
CSL Limited did not pass any screens on 8/20/2026.
